VLP Delivery

VLP Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation vaccines and therapeutic agents using its proprietary Virus-Like Particle (VLP) and self-amplifying RNA (saRNA) platforms. Founded by Dr. Wataru Akahata, the company leverages its iVLP technology to create highly immunogenic, non-infectious particles that mimic the structure of viruses to elicit potent immune responses. Their lead program, VLPCOV-01, is a saRNA-based COVID-19 vaccine currently in clinical development in Japan, while their pipeline also includes a promising malaria vaccine and several cancer immunotherapies. With operations in Gaithersburg, Maryland, San Diego, California, and Japan, VLP Therapeutics is positioned to address significant unmet needs in infectious diseases, oncology, and neurology. The company's approach aims to provide more durable and effective protection compared to traditional vaccine technologies.